Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Cholesterol and lipoprotein metabolism compounds target sterol synthesis and lipoprotein handling. Cholesterol is built through the mevalonate pathway, which also yields farnesyl and geranylgeranyl pyrophosphate for protein prenylation. Lapaquistat acetate and L-731120 inhibit squalene synthase, the branch point that commits farnesyl pyrophosphate to sterol synthesis. NE 10790 acts on farnesyl pyrophosphate synthase (FPPS), while hGGPPS-IN-1 blocks human geranylgeranyl pyrophosphate synthase. Intracellular sterol transport is addressed by Y18501, an inhibitor of oxysterol-binding protein (OSBP). Pelacarsen sodium is an antisense oligonucleotide directed against apolipoprotein(a), the protein that distinguishes lipoprotein(a) from low-density lipoprotein particles.
Lp(a)-IN-8 is a selective antagonist of lipoprotein(a) [Lp(a)], a recognized causal risk factor for atherosclerotic cardiovascular disease (ASCVD). This compound effectively inhibits Lp(a) accumulation, offering potential for reducing cardiovascular risk. Research applications include investigations into ASCVD mechanisms and therapeutic strategies targeting Lp(a) modulation.
Out of stock
All 3 sizes